For example, synthetic FXR agonists, such as compound 33, exhibit strong anti-inflammatory activity and the ability to repair colonic epithelium in the DSS-induced acute colitis model, suggesting their potential as candidate drugs for IBD treatment [470]. This evidence concerns the gene NR1H4 and inflammatory bowel disease.